Dong-A ST and Gradient Bio-Convergence Sign a Joint Research Agreement on New Drug Development Using AI-based organoids and dielectric Analysis

Aug 22, 2025

Dong-A ST and Gradient Bio-Convergence Sign a Joint Research Agreement on New Drug Development Using AI-based organoids and dielectric Analysis



As the U.S. Food and Drug Administration (FDA) announced its plan to phase out animal testing obligations in the drug development process, companies related to animal replacement tests such as organoids (mini organs) and artificial intelligence (AI) are drawing attention, and Dong-A ST and Gradient BioConvergence signed a joint research agreement in the early stages of new drug development using AI-based organoid and dielectric analysis.

Through this agreement held at the Dong-A ST Yongin Research Complex on the 21st, the two companies will cooperate to discover new targets and develop new drugs through analysis of ▲AI-based organoids and dielectric big data, analyze drug responses of various carcinomas using ▲Patient-Derived Organoid (PDO), and screen precision medical-based drugs using human-indented Pluripotent Stem Cell (HiPSC)-based brain organoids to verify the effectiveness of candidates for refractory brain diseases such as Alzheimer's disease and tauopathy.

Gradient BioConvergence is a company with more than 80% of its employees consisting of researchers, with approximately 1000 species of PDOs and an organoid banking system based on genomic information (NGS) data. It is an organoid-based target discovery company that discovers new anticancer targets through its own AI platform and CRISPR-Cas9 technology, and specializes in organoid-based target discovery with key platforms such as organoid construction and drug screening services derived from iPSC (indicated pluripotent stem cells).




Lee Jin-geun, CEO of Gradient BioConvergence, said, "The organoid platform of Gradient BioConvergence and Dong-A ST's new drug development capabilities will meet to greatly increase precision and efficiency in the early stages of new drug development. We will combine the technologies and resources of both companies to lead new drug development more quickly and effectively."

Kim Mi-kyung, head of the Dong-A ST research division, said "When both companies' technology and research capabilities are combined, it will be possible to discover independent drug targets and select effective candidates."We will work closely with Gradient BioConvergence to create innovative research results and strengthen the competitiveness of global new drug development."





This article was translated by Naver AI translator.